S100 protein, CSF
S100 proteins constitute a family of more than 20 calcium-binding proteins characterized by EF-hand motifs. They regulate cytoskeletal dynamics, enzyme activity, intracellular calcium homeostasis, and signal transduction. Key isoforms include S100A1, S100B, S100A4, and S100A6. These proteins act through autocrine and paracrine signaling, binding to heparan sulfate proteoglycans, G-protein–coupled receptors, and scavenger receptors.
In the central nervous system (CNS), S100 proteins modulate synaptic activity, promote neurogenesis, and regulate astrocyte–neuron interactions. Elevated levels of S100B in cerebrospinal fluid (CSF) and serum are biomarkers of neuronal injury, neuroinflammation, and blood–brain barrier disruption. Clinically, S100 proteins have been implicated in neurodegenerative diseases such as Alzheimer’s disease and Creutzfeldt–Jakob disease, in acute conditions such as traumatic brain injury and stroke, and in psychiatric disorders. Beyond neurology, dysregulation of S100 proteins has diagnostic and prognostic value in cancers particularly melanoma, where S100B is an established tumor marker. S100A1 dysregulation has been linked to heart failure.
- As an aid in the diagnosis of neurodegenerative diseases (e.g., Alzheimer’s disease, Creutzfeldt–Jakob disease)
- Can serve as a biomarker for brain injury, stroke, and traumatic brain injury
- Monitoring therapeutic response in neurological and oncological disorders especially melanoma and breast cancer
Increased levels:
- Alzheimer’s disease
- Creutzfeldt–Jakob disease
- Parkinson’s disease
- Traumatic brain injury
- Stroke
- Malignancies (especially melanoma, but also breast and pancreatic cancers)
- Autoimmune and chronic inflammatory diseases
- Heart failure
Decreased levels:
- Certain CNS injuries with neuronal loss
- Sepsis (due to immunologic dysregulation)
| Age Range | Reference Interval |
|---|---|
| 19 years and older | 0 – 96 ng/L |
| 3 years to 19 years | ≤ 160 ng/L |
| 25 months to 3 years | ≤ 170 ng/L |
| 10 months to 25 months | ≤ 230 ng/L |
| 5 months to 10 months | ≤ 350 ng/mL |
| 0 days to 5 months | ≤ 510 ng/mL |
Cerebrospinal fluid collected in a sterile container or tube.
Stability
- Ambient: 4 hrs.
- Refrigerated: 3-5 days
- Frozen: 90 days
- Curr Mol Med. 2013 Jan;13(1):24-57. [PMID: 22834835]
- Front Biosci. 2002 May 1;7:d1356-68. doi: 10.2741/A846. [PMID: 11991838]
- Int J Biochem Cell Biol. 2001 Jul;33(7):637-68. [PMID: 11390274]
- Melanoma Res. 2019 Feb;29(1):23-29. [PMID: 30216200]